Pharmaceutical Raw Materials

Diquafosol Tetrasodium (Diquafosol Tetrasodium Tetrasodium), chemically known as P1,P4-di(uridine 5'-tetrahydrogen tetraphosphate) sodium, was jointly developed by Santen Pharmaceuticals, Inc. and Inspire Pharmaceuticals, Inc. and was launched in Japan in 2010 under the trade name Diquas, and Diquafosol Tetrasodium Eye Drops had sales of approximately $100 million in 2017 . Diquafosol Tetrasodium Eye Drops is the first P2Y2 receptor agonist eye drops approved for marketing in the world, which acts on the P2Y2 receptor on the conjunctival epithelium and cuprocyte membranes to improve the symptoms of dry eye disease by up-regulating the concentration of intracellular calcium ions, and promoting the secretion of water and mucin, thus bringing the tear film closer to its normal state. In addition, Diquafosol Tetrasodium Eye Drops is a compound expected to be developed as a depyritizing agent with phlegm-inducing effects or as a therapeutic agent for pneumonia.